114525-94-9

Upstream product

• 540-88-5 acetic acid tert-butyl ester 
• 2566-30-5 N-Methyl-L-phenylalanine 
• 63-91-2 L-phenylalanine 
• 115-11-7 isobutene 
• 2899-07-2 (S)-N-benzyloxycarbonyl-N-methyl-phenyl alanine 
• 845777-57-3 N-(o-nitrobenzenesulfonyl)-N-methyl-L-phenylalanine tert-butyl ester 
• 61900-41-2 (S)-tert-butyl-2-formamido-3-phenylpropanoate 
• 114525-93-8 Cbz-(Me)Phe-Ot-Bu 
• 1161-13-3 N-Cbz-L-Phe 
• 247167-07-3 N-(o-nitrobenzenesulfonyl)-L-phenylalanine tert-butyl ester 
• 16874-17-2 L-phenylalanine tert-butyl ester 

Downstream Products

• 593252-97-2 (S)-2-Benzyloxycarbonylamino-3-methyl-butyric acid (S)-1-[((S)-1-tert-butoxycarbonyl-2-phenyl-ethyl)-methyl-carbamoyl]-2-methyl-propyl ester 
• 845777-62-0 (S)-2-(Methyl-{(S)-3-methyl-2-[methyl-(2-nitro-benzenesulfonyl)-amino]-butyryl}-amino)-3-phenyl-propionic acid tert-butyl ester 
• 871732-96-6 (S)-2-(Methyl-{(S)-3-methyl-2-[methyl-((S)-3-methyl-2-methylamino-butyryl)-amino]-butyryl}-amino)-3-phenyl-propionic acid tert-butyl ester 
• 871733-04-9 (S)-2-{Methyl-[(S)-3-methyl-2-(methyl-{(S)-3-methyl-2-[methyl-((S)-3-methyl-2-methylamino-butyryl)-amino]-butyryl}-amino)-butyryl]-amino}-3-phenyl-propionic acid tert-butyl ester 
• 871732-87-5 (S)-2-{Methyl-[(S)-3-methyl-2-(methyl-{(S)-3-methyl-2-[methyl-(2-nitro-benzenesulfonyl)-amino]-butyryl}-amino)-butyryl]-amino}-3-phenyl-propionic acid tert-butyl ester 
• 871732-88-6 (S)-2-[Methyl-((S)-3-methyl-2-{methyl-[(S)-3-methyl-2-(methyl-{(S)-3-methyl-2-[methyl-(2-nitro-benzenesulfonyl)-amino]-butyryl}-amino)-butyryl]-amino}-butyryl)-amino]-3-phenyl-propionic acid tert-butyl ester 
• 871732-95-5 (S)-2-[Methyl-((S)-3-methyl-2-{methyl-[(S)-3-methyl-2-(methyl-{(S)-3-methyl-2-[methyl-((R)-2-methyl-oct-7-ynoyl)-amino]-butyryl}-amino)-butyryl]-amino}-butyryl)-amino]-3-phenyl-propionic acid tert-butyl ester 
• 871733-05-0 (S)-2-[Methyl-((S)-3-methyl-2-{methyl-[(S)-3-methyl-2-(methyl-{(S)-3-methyl-2-[methyl-((S)-2-methyl-oct-7-ynoyl)-amino]-butyryl}-amino)-butyryl]-amino}-butyryl)-amino]-3-phenyl-propionic acid tert-butyl ester 
• 1418192-89-8 C₃₃H₄₀N₂O₆ 
• 1418192-73-0 C₄₆H₆₅N₅O₁₀S 
• 1418192-50-3 O-methylulongamide C 
• 1418192-57-0 C₂₅H₃₄N₂O₄ 
• 914482-22-7 (R)-3-{[2-((S)-1-tert-Butoxycarbonylamino-ethyl)-thiazole-4-carbonyl]-amino}-pentanoic acid (S)-1-({(S)-1-[((S)-1-tert-butoxycarbonyl-2-phenyl-ethyl)-methyl-carbamoyl]-2-methyl-propyl}-methyl-carbamoyl)-ethyl ester 
• 909546-92-5 (S)-3-{[2-((S)-1-tert-Butoxycarbonylamino-ethyl)-thiazole-4-carbonyl]-amino}-pentanoic acid (S)-1-({(S)-1-[((S)-1-tert-butoxycarbonyl-2-phenyl-ethyl)-methyl-carbamoyl]-2-methyl-propyl}-methyl-carbamoyl)-ethyl ester 

Relevant academic research and scientific papers

7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER

The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.

7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER

The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.

7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION

The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds as TLR7 agonists for the treatment of viral infections.

Design, synthesis, and optimization of balanced dual NK1/NK 3 receptor antagonists

In connection with a program directed at potent and balanced dual NK 1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pKi values of 8.6 and 8.1, respectively.

Synthesis of o -me ulongamide b and o -me ulongamide c, natural modified cyclodepsipeptides

Synthesis of O-Me ulongamide B and O-Me ulongamide C, modified natural cyclodepsipeptides, was achieved by a convergent route. The respective dipeptides and tridepsipeptides were coupled, obtaining linear depsipentapeptides, which were then deprotected and cyclized. These compounds were tested against three different types of human carcinoma cells and showed only moderate activity.

Synthesis and biological evaluation of analogues of the marine cyclic depsipeptide obyanamide

On the basis of the total synthesis of obyanamide, 20 analogues of this marine cyclic depsipeptide have been synthesized by (i) preparation of the tripeptide fragments in the western hemisphere using Z/OtBu protocol; (ii) preparation of the dipeptide fragments in the eastern hemisphere using Boc/OMe protocol; and (iii) fragments coupling, removal of protecting groups (Boc and OtBu, in one pot), and macrocyclizaion in the last step. The cytotoxic test showed that three synthetic compounds exhibited moderate activities against HL-60, KB, LOVO, and A549 cell lines. According to the results, the β-amino acid residue was found to play a critical role in the biological activities. Additionally, the ester bond along with the Ala(Thz) moiety was also essential for biological activities. However, it seems too early to draw a conclusion that the N-methylation of Val/Phe can lead to higher or lower cytotoxic activities.

Total synthesis and reassignment of stereochemistry of obyanamide

The total synthesis of a marine cytotoxic cyclic depsipeptide obyanamide is reported. The synthesis has led to a reassignment of the C-3 configuration in β-amino acid residue. And this revision is also supported by biological test.

The total synthesis and reassignment of stereochemistry of dragonamide

The first total synthesis of dragonamide is reported. The synthesis has led to a reassignment of the configuration at the stereogenic centre on the alkyne-bearing fragment of the molecule.

The total synthesis and stereochemical revision of yanucamide A

(Matrix presented) The first total synthesis of yanucamide A is reported via amide and ester couplings of the key components. This synthesis has established the configuration at the previously ambiguous 3-position, and also revised the stereochemistry at the 22-position, to give 3S,12S,17S,22S for the natural product.